BiotechTube
ID Genomics

ID Genomics

Seattle, United States· Est.
idgenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.3M

Overview

ID Genomics is a private, pre-revenue diagnostics company tackling the global antibiotic resistance crisis through a proprietary platform that 'barcodes' bacterial strains to predict drug susceptibility. Its lead product, CLoNeT™, is in development for urinary tract infections (UTIs) and has shown promising preclinical results in dramatically reducing prescription errors. The company complements its assay development with a growing big-data repository, BactNet™, and offers a suite of microbial genomic analysis services. Its approach aims to shift infectious disease management from empirical treatment to precise, data-driven therapy.

Infectious DiseasesUrinary Tract Infections

Technology Platform

Proprietary bacterial DNA 'barcoding' assay (CLoNeT™) linked to a big-data metadata repository (BactNet™) that matches barcodes to antibiotic susceptibility profiles.

Funding History

2
Total raised:$5.3M
Series A$5M
Grant$300K

Opportunities

The global antibiotic resistance crisis creates a massive, urgent need for rapid precision diagnostics, particularly for high-volume infections like UTIs.
The adaptable platform allows for expansion into other bacterial and potentially fungal infections.
The service business provides a revenue stream and data-generation engine.

Risk Factors

Clinical validation of the CLoNeT™ assay is pending.
Commercial adoption requires changing clinical practice and competing with established diagnostic methods.
The business model is capital-intensive, and the company operates in a highly competitive landscape.

Competitive Landscape

ID Genomics competes with large diagnostic companies (e.g., BioMérieux, Becton Dickinson) offering automated culture and susceptibility systems, and with molecular diagnostic firms developing rapid PCR- and sequencing-based resistance tests. Its differentiation lies in the specific barcoding approach linked to a predictive database.

More companies in Diagnostics & Precision Medicine →More companies in United States →